Physician profile
Richard Scher
NPI 1043205313
$7,419.83
in general payments reported to CMS, 2019-2025
14 companies · $85.08 in 2025
The $85.08 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,227 · 2020: $1,102 · 2021: $1,275 · 2022: $26.85 · 2023: $15.93 · 2024: $2,688 · 2025: $85.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,600 · Food and Beverage: $137 · Education: $51.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,600.00 |
| Food and Beverage | $137.49 |
| Education | $51.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,613.17 | 2021-2024 | Imfinzi |
| Kite Pharma, INC. | $1,770.48 | 2019 | |
| Epizyme, INC. | $1,250.00 | 2021 | |
| Taiho Oncology, INC. | $1,087.50 | 2020 | |
| Athenex Pharmaceutical Division, LLC | $356.44 | 2019 | |
| Comsort, INC | $100.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $64.21 | 2022-2025 | Opdualag, Krazati |
| Gilead Sciences, INC. | $56.98 | 2021-2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $51.06 | 2024 | Libtayo |
| Lilly USA, LLC | $22.26 | 2024 | |
| Celgene Corporation | $16.88 | 2025 | Reblozyl |
| Eisai INC. | $15.93 | 2023 | |
| Janssen Biotech, INC. | $14.92 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$30,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Scher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.